RATIONALE: Lymphangioleiomyomatosis (LAM), occurring sporadically (S-LAM) or in patients with tuberous sclerosis complex (TSC), results from abnormal proliferation of LAM cells exhibiting mutations or loss of heterozygosity (LOH) of the TSC genes, TSC1 or TSC2. OBJECTIVES: To identify molecular markers useful for isolating LAM cells from body fluids and determine the frequency of TSC1 or TSC2 LOH. METHODS: Candidate cell surface markers were identified using gene microarray analysis of human TSC2⁻(/)⁻ cells. Cells from bronchoalveolar lavage fluid (BALF), urine, chylous effusions, and blood were sorted based on reactivity with antibodies against these proteins (e.g., CD9, CD44v6) and analyzed for LOH using TSC1- and TSC2-related microsatellite markers and single nucleotide polymorphisms in the TSC2 gene. MEASUREMENTS AND MAIN RESULTS: CD44v6(+)CD9(+) cells from BALF, urine, and chyle showed TSC2 LOH in 80%, 69%, and 50% of patient samples, respectively. LAM cells with TSC2 LOH were detected in more than 90% of blood samples. LAM cells from different body fluids of the same patients showed, in most cases, identical LOH patterns, that is, loss of alleles at the same microsatellite loci. In a few patients with S-LAM, LAM cells from different body fluids differed in LOH patterns. No patients with S-LAM with TSC1 LOH were identified, suggesting that TSC2 abnormalities are responsible for the vast majority of S-LAM cases and that TSC1-disease may be subclinical. CONCLUSIONS: Our data support a common genetic origin of LAM cells in most patients with S-LAM, consistent with a metastatic model. In some cases, however, there was evidence for genetic heterogeneity between LAM cells in different sites or within a site.
RATIONALE: Lymphangioleiomyomatosis (LAM), occurring sporadically (S-LAM) or in patients with tuberous sclerosis complex (TSC), results from abnormal proliferation of LAM cells exhibiting mutations or loss of heterozygosity (LOH) of the TSC genes, TSC1 or TSC2. OBJECTIVES: To identify molecular markers useful for isolating LAM cells from body fluids and determine the frequency of TSC1 or TSC2 LOH. METHODS: Candidate cell surface markers were identified using gene microarray analysis of humanTSC2⁻(/)⁻ cells. Cells from bronchoalveolar lavage fluid (BALF), urine, chylous effusions, and blood were sorted based on reactivity with antibodies against these proteins (e.g., CD9, CD44v6) and analyzed for LOH using TSC1- and TSC2-related microsatellite markers and single nucleotide polymorphisms in the TSC2 gene. MEASUREMENTS AND MAIN RESULTS: CD44v6(+)CD9(+) cells from BALF, urine, and chyle showed TSC2 LOH in 80%, 69%, and 50% of patient samples, respectively. LAM cells with TSC2 LOH were detected in more than 90% of blood samples. LAM cells from different body fluids of the same patients showed, in most cases, identical LOH patterns, that is, loss of alleles at the same microsatellite loci. In a few patients with S-LAM, LAM cells from different body fluids differed in LOH patterns. No patients with S-LAM with TSC1 LOH were identified, suggesting that TSC2 abnormalities are responsible for the vast majority of S-LAM cases and that TSC1-disease may be subclinical. CONCLUSIONS: Our data support a common genetic origin of LAM cells in most patients with S-LAM, consistent with a metastatic model. In some cases, however, there was evidence for genetic heterogeneity between LAM cells in different sites or within a site.
Authors: Denise M Crooks; Gustavo Pacheco-Rodriguez; Rosamma M DeCastro; J Philip McCoy; Ji-an Wang; Fumiyuki Kumaki; Thomas Darling; Joel Moss Journal: Proc Natl Acad Sci U S A Date: 2004-12-06 Impact factor: 11.205
Authors: S Povey; M W Burley; J Attwood; F Benham; D Hunt; S J Jeremiah; D Franklin; G Gillett; S Malas; E B Robson Journal: Ann Hum Genet Date: 1994-05 Impact factor: 1.670
Authors: Xiaole Mao; Ahmad Ahsan Nawaz; Sz-Chin Steven Lin; Michael Ian Lapsley; Yanhui Zhao; J Philip McCoy; Wafik S El-Deiry; Tony Jun Huang Journal: Biomicrofluidics Date: 2012-04-20 Impact factor: 2.800
Authors: Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss Journal: Am J Respir Cell Mol Biol Date: 2018-06 Impact factor: 6.914
Authors: Li Zhang; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Jiro Kato; Mary Haughey; Joseph R Fontana; Vincent C Manganiello; Joel Moss Journal: Am J Respir Crit Care Med Date: 2015-02-01 Impact factor: 21.405
Authors: Wendy K Steagall; Li Zhang; Xiong Cai; Gustavo Pacheco-Rodriguez; Joel Moss Journal: Am J Respir Crit Care Med Date: 2015-04-01 Impact factor: 21.405
Authors: Francis X McCormack; William D Travis; Thomas V Colby; Elizabeth P Henske; Joel Moss Journal: Am J Respir Crit Care Med Date: 2012-12-15 Impact factor: 21.405
Authors: Xiong Cai; Gustavo Pacheco-Rodriguez; Mary Haughey; Leigh Samsel; Suowen Xu; Hai-Ping Wu; J Philip McCoy; Mario Stylianou; Thomas N Darling; Joel Moss Journal: Chest Date: 2014-01 Impact factor: 9.410
Authors: Ahmad Ahsan Nawaz; Xiangjun Zhang; Xiaole Mao; Joseph Rufo; Sz-Chin Steven Lin; Feng Guo; Yanhui Zhao; Michael Lapsley; Peng Li; J Philip McCoy; Stewart J Levine; Tony Jun Huang Journal: Lab Chip Date: 2013-11-28 Impact factor: 6.799
Authors: Francis X McCormack; Nishant Gupta; Geraldine R Finlay; Lisa R Young; Angelo M Taveira-DaSilva; Connie G Glasgow; Wendy K Steagall; Simon R Johnson; Steven A Sahn; Jay H Ryu; Charlie Strange; Kuniaki Seyama; Eugene J Sullivan; Robert M Kotloff; Gregory P Downey; Jeffrey T Chapman; MeiLan K Han; Jeanine M D'Armiento; Yoshikazu Inoue; Elizabeth P Henske; John J Bissler; Thomas V Colby; Brent W Kinder; Kathryn A Wikenheiser-Brokamp; Kevin K Brown; Jean F Cordier; Cristopher Meyer; Vincent Cottin; Jan L Brozek; Karen Smith; Kevin C Wilson; Joel Moss Journal: Am J Respir Crit Care Med Date: 2016-09-15 Impact factor: 21.405